Home › Funds › Kimelman & Baird, LLC › REGN
Kimelman & Baird, LLC position in REGN
REGENERON PHARMACEUTICALS · Health Care
Kimelman & Baird, LLC reported holding 27,628 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$20.9M, representing 1.58% of its reported portfolio and ranking #24 among its reported holdings. Kimelman & Baird, LLC has disclosed REGN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-04 · Source: SEC EDGAR Form 13F-HR
How Kimelman & Baird, LLC's REGN position evolved
Kimelman & Baird, LLC first disclosed a stake in REGN in Q2 2024 at 54 shares (US$57K). The position peaked in Q3 2026 at 27,628 shares, worth US$20.9M. Across 10 filings, Kimelman & Baird, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 27,628 shares valued at US$20.9M. Notable position changes include a 481% increase in Q4 2025 (shares were roughly flat over the following quarter), a 3357% increase in Q1 2026 (shares fell 18% over the following quarter), a 155% increase in Q2 2026 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 54 | $56.76K | New |
| Q3 2024 | 54 | $56.77K | Hold |
| Q4 2024 | 54 | $38.47K | Hold |
| Q1 2025 | 54 | $34.25K | Hold |
| Q2 2025 | 54 | $28.35K | Hold |
| Q3 2025 | 54 | $30.36K | Hold |
| Q4 2025 | 314 | $242.37K | Add |
| Q1 2026 | 10.86K | $8.39M | Add |
| Q2 2026 | 27.67K | $17.25M | Add |
| Q3 2026 | 27.63K | $20.95M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on Kimelman & Baird, LLC
FAQ
How long has Kimelman & Baird, LLC held REGN?
Kimelman & Baird, LLC has disclosed REGN holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Kimelman & Baird, LLC's current position in REGN?
As of Q3 2026, Kimelman & Baird, LLC holds 27.63K shares of REGN (REGENERON PHARMACEUTICALS), valued at $20.95M, representing 1.58% of its reported portfolio and ranking #24.
Has Kimelman & Baird, LLC been buying or selling REGN?
In the latest 13F filing (Q3 2026), Kimelman & Baird, LLC held unchanged its position in REGN. The position peaked in Q3 2026 at 27.63K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.